NateraNTRA
NTRA
About: Natera Inc is a diagnostic and research company with proprietary molecular and bioinformatics technology. The company's key product offerings include its Panorama Non-Invasive Prenatal Test (NIPT) which screens for chromosomal abnormalities of a fetus as well as in twin pregnancies, typically with a blood draw from the mother, Horizon Carrier Screening (HCS) to determine carrier status for a large number of severe genetic diseases that could be passed on to the carrier's children, Signatera molecular residual disease (MRD) test, which detects circulating tumor DNA in patients previously diagnosed with cancer to assess molecular residual disease and monitor for recurrence; and Prospera, to assess organ transplant rejection.
Employees: 4,434
0
Funds holding %
of 7,425 funds
0
Analysts bullish %
of 6 analysts
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
284% more first-time investments, than exits
New positions opened: 142 | Existing positions closed: 37
30% more capital invested
Capital invested by funds: $15.3B [Q3] → $19.8B (+$4.52B) [Q4]
21% more funds holding in top 10
Funds holding in top 10: 24 [Q3] → 29 (+5) [Q4]
20% more funds holding
Funds holding: 488 [Q3] → 584 (+96) [Q4]
4.53% more ownership
Funds ownership: 97.2% [Q3] → 101.72% (+4.53%) [Q4]
11% less repeat investments, than reductions
Existing positions increased: 183 | Existing positions reduced: 205
17% less call options, than puts
Call options by funds: $136M | Put options by funds: $163M
Research analyst outlook
6 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$160
6%
upside
Avg. target
$197
31%
upside
High target
$251
66%
upside
6 analyst ratings
6 positive
100%
0 neutral
0%
0 negative
0%
Barclays Luke Sergott 36% 1-year accuracy 21 / 59 met price target | 6%upside $160 | Overweight Maintained | 10 Apr 2025 |
RBC Capital Conor McNamara 17% 1-year accuracy 7 / 41 met price target | 66%upside $251 | Outperform Initiated | 13 Mar 2025 |
Morgan Stanley Tejas Savant 26% 1-year accuracy 5 / 19 met price target | 23%upside $185 | Overweight Maintained | 5 Mar 2025 |
Piper Sandler David Westenberg 45% 1-year accuracy 19 / 42 met price target | 36%upside $205 | Overweight Maintained | 4 Mar 2025 |
Canaccord Genuity Kyle Mikson 33% 1-year accuracy 9 / 27 met price target | 29%upside $195 | Buy Maintained | 28 Feb 2025 |
Financial journalist opinion
Based on 6 articles about NTRA published over the past 30 days
Neutral
Business Wire
1 day ago
Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced the results of its DEFINE-HT clinical trial in heart transplantation, which were shared today, April 29, 2025, in an oral presentation at the International Society for Heart and Lung Transplantation 45th Annual Meeting in Boston, MA. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-der.
Positive
Seeking Alpha
1 day ago
Baron Health Care Fund Q1 2025 Top Net Purchases And Sales
Initiated positions in Waters Corporation, Penumbra, McKesson, Masimo, and added to UnitedHealth Group due to strong market positions and growth potential. Waters Corporation's growth driven by biopharmaceutical quality control, new regulations, and product replacement cycles, targeting high single to low double-digit revenue growth. Penumbra's mechanical thrombectomy devices target underpenetrated markets with potential FDA approval for Thunderbolt device as a growth catalyst.
Neutral
Business Wire
6 days ago
Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that its ultra-sensitive Signatera Genome assay is now broadly available to physicians in the United States. This launch is supported by a large genome-based molecular residual disease (MRD) study, which was accepted and will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. In this clinical validation study of more than 3,000 sam.
Neutral
Business Wire
1 week ago
Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced that data from 8 studies will be shared at the American Association of Cancer Research (AACR) Annual Meeting that will take place April 25 – 30, 2025 in Chicago, IL. Highlights from AACR include: An oral presentation titled “Large-scale Genomic Profiling of Colorectal Cancer” from an exploratory analysis examining the characteristics of the mutational landscape of C.
Positive
Investors Business Daily
1 week ago
The Blood Test Revolution: It's A New Day In Cancer. Guardant, Natera And Exact Are Here For It.
A revolution in oncology could help the 18 million cancer survivors in the U.S. and bolster Guardant Health, Natera and Exact Sciences.
Positive
The Motley Fool
3 weeks ago
27.5% of Stanley Druckenmiller's $3.7 Billion Portfolio Is Invested in These 3 Under-the-Radar AI Stocks
Stanley Druckenmiller is in an elite league of investors that includes the likes of Warren Buffett. He ran his hedge fund firm, Duquesne Capital Management, for 30 years, posting eye-popping average annual returns of 30%.
Neutral
Business Wire
1 month ago
DEFINE-HT Selected for Late-Breaking Oral Presentation at ISHLT Annual Meeting
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, announced that it will share results from the DEFINE-HT study in a late-breaking oral presentation at the International Society for Heart and Lung Transplantation (ISHLT) 45th Annual Meeting on April 29, 2025. DEFINE-HT is the first prospective, multicenter study in heart transplant recipients designed to assess whether elevated levels of donor-derived cell-free DNA (dd-cfDNA), as.
Neutral
The Motley Fool
1 month ago
Here Are Billionaire Stanley Druckenmiller's 5 Biggest Stock Holdings
Stanley Druckenmiller, whose net worth is around $6.9 billion, made most of his fortune as a hedge fund manager, and became a well-known name on Wall Street while working for George Soros until 2000.
Positive
Seeking Alpha
1 month ago
Natera: Growth Looks Unstoppable, Positive EPS Just A Matter Of Time
Natera Inc. shows robust growth with high margins, a strong genetic testing portfolio, and a recent pullback offering an attractive entry point for investors.
Neutral
Business Wire
1 month ago
Natera Announces Enrollment of First Patients in the HEROES Clinical Trial in Metastatic HER2+ Breast Cancer
AUSTIN, Texas--(BUSINESS WIRE)--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and genetic testing, today announced the enrollment of the first patients in the HEROES clinical trial. HEROES is a multi-center, phase II trial that explores the discontinuation or de-escalation of anti-HER2 targeted therapy among patients with metastatic HER2+ breast cancer. The trial is supported by funding from the French Ministry of Health through the Hospital Clinical Research Program (PHRC) and.
Charts implemented using Lightweight Charts™